FDA Extends Review for Astellas Pharma Inc. (Jobs) Fungal Drug New Use

September 4, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

TOKYO, Sept 3 (Reuters) - U.S. health authorities have extended by three months their review of Astellas Pharma Inc's application for fungal drug Mycamine to be used for additional indications, the company said on Monday.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory Asia

Astellas Pharma US, Inc. Food and Drug Administration (FDA)